Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RO5024048 + Danoprevir/r + Peg/Rib in HCV GT1 Prior PI Failures
NCT01579019Phase 2Withdrawn
- Sponsor
- Roche
- Start
- Jul 2012
- Primary completion
- Mar 2014
- Modality
- Small Molecules
01
Overview
A Phase 2 trial of mericitabine in hepatitis C (HCV), sponsored by Roche. Planned start Jul 2012; status: withdrawn.
02
Drugs
mericitabine
03
Conditions
hepatitis C (HCV)
Beyond the preview
Go deeper on NCT01579019.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01579019.